Perioperative BRAF inhibitors in locally advanced stage III melanoma

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Stage III malignant melanoma is heterogeneous, with advanced cases often incurable by surgery alone.
• BRAF mutations, particularly V600E, are common in melanoma and are targets for specific therapies.
• Targeted BRAF inhibitors have rarely been utilized in the neoadjuvant setting for melanoma.

Purpose of the Study:

• To evaluate the efficacy of neoadjuvant BRAF inhibitors in patients with Stage III malignant melanoma.
• To assess the impact of these agents on surgical resectability and pathological response.
• To determine the disease-free survival rates following perioperative BRAF inhibitor treatment.

Main Methods:

• Thirteen patients with BRAFV600E-mutated, regionally advanced melanoma received BRAF inhibitors pre-operatively.
• Surgical resection was performed following neoadjuvant treatment.
• Primary outcomes included successful resection and pathological response; disease-free survival was a secondary outcome.

Main Results:

• Twelve out of thirteen patients demonstrated significant clinical response, enabling complete macroscopic resection.
• Four patients achieved a complete pathological response, with no viable tumor found post-surgery.
• At a median follow-up of 20 months, ten patients remained disease-free; one patient progressed and died.

Conclusions:

• Perioperative BRAF inhibitor treatment is effective in facilitating surgical resection for BRAFV600E-mutated Stage III melanoma.
• This neoadjuvant strategy leads to favorable pathological responses and satisfactory disease-free survival.
• Targeted therapy with BRAF inhibitors represents a viable approach for managing advanced melanoma.